Ad hoc announcement pursuant to article 53 LR of the SIX Swiss Exchange DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors
Dottikon, Switzerland, July 4, 2025 - The shareholders approved all proposals of the Board of Directors at the 20th Annual General Meeting of Dottikon ES Holding AG held in Dottikon. At the beginning of the Annual General Meeting, the 362 present shareholders represented 12'507'056 voting rights or 93.5% of the total of 13'372'464 registered shares with voting rights.
The Annual Report, the financial statements 2024/25, and the Group financial statements 2024/25 of Dottikon ES Holding AG were approved by the Annual General Meeting. The Reporting on Non-Financial Matters 2024 of Dottikon ES Holding AG was also approved. The Compensation Report 2024/25 was approved in a consultative voting by the Annual General Meeting. Discharge for the business year 2024/25 was granted to the responsible members of the Board of Directors and Senior Management. The proposal of the Board of Directors to carry forward the entire retained earnings to new account and to pay no dividend was accepted. The proposal for revision of the By-Laws regarding remuneration principles was approved. The previous Chairman of the Board of Directors Dr. Markus Blocher was confirmed for another one-year term. In addition, Dr. Pierre-Alain Ruffieux was reelected for a one-year term as Deputy Chairman and Dr. Bernhard Urwyler as member of the Board. Dr. Urs Brändli was elected as member of the Board for one year. All four Board members were elected for a term of one year as members of the Compensation Committee, with Dr. Markus Blocher acting as its Chairman and Dr. Pierre-Alain Ruffieux
as Deputy Chairman. The prospective approval of the maximum amounts of future remunerations for the Board of Directors and Senior Management, respectively, was granted. KPMG AG, Zug, was reelected as external auditor for another one-year term. Dr. iur. Michael Wicki, attorney-at-law and notary public, was reelected as independent proxy until and for the 21st Annual General Meeting.
DOTTIKON ES manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical, biotech, and pharmaceutical industry. The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and positions itself as strategic development and manufacturing partner and performance leader. Its safety culture created over more than 110 years guides the innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing in order to challenge, tighten, or shorten conventional chemical synthesis routes, improve selectivities, yields, and purities, as well as avoid and reduce energy consumption, waste, and CO2 emissions sustainably. The versatile technology and equipment portfolio is used, maintained, and continuously expanded to design, develop, and optimize chemical processes and technical manufacturing procedures for the rapid scale-up from kilograms to multi-tons in order to produce and deliver the respective market volumes.
DOTTIKON ES' one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development and management, clear and transparent data and process documentation, and close customer communication.
Dottikon ES Holding AG is listed on the SIX Swiss Exchange. Symbol: DESN
Security number: 58258171 ISIN: CH0582581713
For further information, please contact Dr. Markus Blocher
CEO
Dottikon ES Holding AG Tel +41 56 616 82 01
investor-relations@dottikon.com
Voting results | ||||
Agenda item | Present voting rights | Appro- val | Rejec- tion | Absten- tion |
1. Approval of Annual Report, financial statements 2024/25 and Group financial statements 2024/25 of Dottikon ES Holding AG | 12'506'621 | 99.9% | 0.0% | 0.1% |
2. Approval of Reporting on Non-Financial Matters 2024 of Dottikon ES Holding AG | 12'506'621 | 99.2% | 0.7% | 0.1% |
3. Compensation Report 2024/25: Consultative voting | 12'506'621 | 96.0% | 3.8% | 0.2% |
4. Discharge for the business year 2024/25 to the members of the Board of Directors and Senior Management | 11'306'231 | 99.3% | 0.6% | 0.1% |
5. Appropriation of retained earnings 2024/25 | 12'506'621 | 99.8% | 0.1% | 0.1% |
6. Revision of By-Laws | 12'506'621 | 99.3% | 0.6% | 0.1% |
| 12'506'621 12'506'621 12'506'621 12'506'621 | 97.1% 99.5% 99.9% 97.8% | 2.9% 0.3% 0.1% 2.1% | 0.0% 0.2% 0.0% 0.1% |
| 12'506'621 12'506'621 12'506'571 12'506'571 | 95.7% 99.1% 98.7% 95.8% | 4.2% 0.8% 1.2% 4.1% | 0.1% 0.1% 0.1% 0.1% |
9. Prospective approval of the maximum amounts of future remunerations for the Board of Directors | 12'506'571 | 99.7% | 0.2% | 0.1% |
10. Prospective approval of the maximum amounts of future remunerations for Senior Management | 12'506'571 | 99.7% | 0.2% | 0.1% |
11. Election of external auditor KPMG AG, Zug | 12'506'571 | 99.7% | 0.1% | 0.2% |
12. Election of independent proxy Dr. iur. Michael Wicki | 12'506'571 | 100.0% | 0.0% | 0.0% |